Phathom Pharmaceuticals Files 8-K
Ticker: PHAT · Form: 8-K · Filed: Aug 19, 2024 · CIK: 1783183
| Field | Detail |
|---|---|
| Company | Phathom Pharmaceuticals, Inc. (PHAT) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $11.50, $11.499, $0.001, $121.7 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Phathom Pharma filed an 8-K, likely with important updates.
AI Summary
Phathom Pharmaceuticals, Inc. filed an 8-K on August 19, 2024, to report other events and financial statements/exhibits. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates a material event or financial update for Phathom Pharmaceuticals, Inc., requiring disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented in the text.
Key Players & Entities
- Phathom Pharmaceuticals, Inc. (company) — Registrant
- August 19, 2024 (date) — Date of earliest event reported
FAQ
What specific events are being reported in this 8-K filing?
The provided text of the 8-K filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items being reported, but does not detail the specific nature of these events.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 19, 2024.
What is the principal executive office address for Phathom Pharmaceuticals, Inc.?
The principal executive offices are located at 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.
What is the telephone number for Phathom Pharmaceuticals, Inc.?
The telephone number for Phathom Pharmaceuticals, Inc. is (877) 742-8466.
What is the Standard Industrial Classification code for Phathom Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Phathom Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,376 words · 6 min read · ~5 pages · Grade level 12.4 · Accepted 2024-08-19 17:13:59
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PHAT The Nasdaq Global Se
- $11.50 — Common Stock"), at an offering price of $11.50 per share, and (ii) with respect to cer
- $11.499 — 22 shares of Common Stock at a price of $11.499 per pre-funded warrant (the "Pre-Funded
- $0.001 — are price for the Shares less a nominal $0.001 per share exercise price for each Pre-F
- $121.7 m — fering are expected to be approximately $121.7 million, before deducting underwriting di
Filing Documents
- d816262d8k.htm (8-K) — 34KB
- d816262dex11.htm (EX-1.1) — 176KB
- d816262dex41.htm (EX-4.1) — 71KB
- d816262dex51.htm (EX-5.1) — 19KB
- d816262dex991.htm (EX-99.1) — 10KB
- g816262g0819053733565.jpg (GRAPHIC) — 3KB
- g816262g0819221127428.jpg (GRAPHIC) — 2KB
- g816262g0819221755969.jpg (GRAPHIC) — 2KB
- 0001193125-24-202879.txt ( ) — 526KB
- phat-20240819.xsd (EX-101.SCH) — 3KB
- phat-20240819_lab.xml (EX-101.LAB) — 18KB
- phat-20240819_pre.xml (EX-101.PRE) — 11KB
- d816262d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated August 19, 2024, by and among Phathom Pharmaceuticals, Inc. and Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Latham & Watkins LLP 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1) 99.1 Press Release dated August 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHATHOM PHARMACEUTICALS, INC. Date: August 19, 2024 By: /s/ Molly Henderson Molly Henderson Chief Financial and Business Officer